Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Monday11 December 2017

The Star : Anti-Cancer application


A Japanese physician and researcher has based his cancer treatment protocol on dendritic cells’ ability to enable selective and effective attack against tumour cells by the body’s own T cells.

SINCE the discovery of dendritic cells by Dr Ralph Steinman in 1973, much research has been carried out to elucidate the basic functional mechanism of dendritic cells.

Many medical research institutes and universities have conducted research in the use of dendritic cells in anti-cancer immunotherapy.

The ability of dendritic cells to enable selective and effective attack against tumour cells by T cells gave rise to great hopes that it would be an ideal cancer treatment.

Read more ...

The Malay Mail : Cancer Cure Is Now In Malaysia


KUALA LUMPUR : There is a new hope for cancer patients in Malaysia. A vaccine widely known for treating late-stage cancer -- almost all types of cancer, except leukemia -- is now available in the country.

The Human Initiated Therapeutic Vaccine (HITV), which was only available in Japan previously, is able to completely destroy microscopic and tiny nests of cancer cells, thus preventing any future recurrences.

Discovered in 2005 by Dr Kenichiro Hasumi, a Japanese physician and researcher, HITV is an autologus (patient derived) active cell-based immunotherapy for metastatic or late-stage cancer patients.

It is based on immunology that harnesses human immune system's innate and adaptive ability to combat diseases.

Read more ...


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks